Trabikibart

N/A

Report date: 2024/09/23 16:32:23

Base Information

Drug NameTrabikibart
Drug Alias NameCSL-311
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionGranulocyte-macrophage colony-stimulating factor receptor antagonistsInterleukin 3 receptor antagonistsInterleukin-5 receptor subunit alpha inhibitors
TargetsInterleukin-5 receptor subunit alphaGranulocyte-macrophage colony-stimulating factor receptorInterleukin 3 receptor
Therapy Area/IndicationsAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCsl Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCsl Behring
Inactive CompaniesN/A
Active IndicationsAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A